Serum biomarkers in a mouse model of bacterial-induced inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 14, Issue 4, 2008, Pages 480-490

  Torrence, Anne E ^a   Brabb, Thea ^a   Viney, Joanne L ^b   Bielefeldt Ohmann, Helle ^c   Treuting, Piper ^a   Seamons, Audrey ^a   Drivdahl, Rolf ^a   Zeng, Weiping ^d   Maggio Price, Lillian ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMGEN INC   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d University of Washington   (United States)

Author keywords

Animal models of IBD; Biomarkers; Inflammation in IBD; Serologic markers testing

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; BISMUTH; FIBRINOGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HAPTOGLOBIN; IMMUNOGLOBULIN A; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 18; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; METRONIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; FEMALE; HELICOBACTER BILIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HELICOBACTER INFECTIONS; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED STRAINS;

EID: 42449095884     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20347     Document Type: Article

References (39)

1. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433.
2. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
3. Malickova K, Janatkova I, Fucikova T, et al. [Initial experience with detection of Saccharomyces cerevisiae antibodies in patients with primary nonspecific inflammatory bowel disease]. Epidemiol Mikrobiol Imunol. 2001;50:131-135.
4. Bouhnik Y. [Diagnostic tools in inflammatory bowel diseases]. Rev Prat. 2005;55:977-983.
5. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822-829.
6. Magro F, Araujo F, Pereira P, et al. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1265-1274.
7. Goke M, Hoffmann JC, Evers J, et al. Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J Gastroenterol. 1997;32:480-486.
8. Nielsen OH, Langholz E, Hendel J, et al. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig Dis Sci. 1994;39:1918-1923.
9. Goggins MG, Goh J, O'Connell MA, et al. Soluble adhesion molecules in inflammatory bowel disease. Ir J Med Sci. 2001;170:107-111.
10. D'Argenio G, Biancone L, Cosenza V, et al. Transglutaminases in Crohn's disease. Gut. 1995;37:690-695.
11. D'Argenio G, Cicacci C, Sorrentini I, et al. Serum transglutaminase in inflammatory bowel diseases. J Clin Gastroenterol. 1990;12:400-404.
12. Furuya D, Yagihashi A, Komatsu M, et al. Serum interleukin-18 concentrations in patients with inflammatory bowel disease. J Immunother. 2002;25:S65-S67.
13. Mahida YR, Gallagher A, Kurlak L, et al. Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease. Clin Exp Immunol. 1990;82:75-80.
14. Nielsen OH, Ciardelli T, Wu Z, et al. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease. Am J Gastroenterol. 1995;90:1301-1306.
15. Bross DA, Leichtner AM, Zurakowski D, et al. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 1996;23:164-171.
16. Mitsuyama K, Tomiyasu N, Suzuki A, et al. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease. Clin Exp Immunol. 2006;143:125-131.
17. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297-1301.
18. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853.
19. Vind I, Johansen JS, Price PA, et al. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003;38:599-605.
20. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309-318.
21. Oz HS, Ray M, Chen TS, et al. Efficacy of a transforming growth factor beta 2 containing nutritional support formula in a murine model of inflammatory bowel disease. J Am Coll Nutr. 2004;23:220-226.
22. Segui J, Gil F, Gironella M, et al. Down-regulation of endothelial adhesion molecules and leukocyte adhesion by treatment with superoxide dismutase is beneficial in chronic immune experimental colitis. Inflamm Bowel Dis. 2005;11:872-882.
23. D'Argenio G, Sorrentini I, Cosenza V, et al. Serum and tissue transglutaminase correlates with the severity of inflammation in induced colitis in the rat. Scand J Gastroenterol. 1992;27:111-114.
24. Maggio-Price L, Shows D, Waggie K, et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol. 2002;160:739-751.
25. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733-5744.
26. Maggio-Price L, Bielefeldt-Ohmann H, Treuting P, et al. Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia. Am J Pathol. 2005;166:1793-1806.
27. Burich A, Hershberg R, Waggie K, et al. Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2001;281:G764-G778.
28. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-1812.
29. Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177:1809-1814.
30. Uguccioni M, Gionchetti P, Robbiani DF, et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol. 1999;155:331-336.
31. Myles MH, Livingston RS, Livingston BA, et al. Analysis of gene expression in ceca of Helicobacter hepaticus-infected A/JCr mice before and after development of typhlitis. Infect Immun. 2003;71:3885-3893.
32. Mohamadzadeh M, Poltorak AN, Bergstressor PR, et al. Dendritic cells produce macrophage inflammatory protein-1 gamma, a new member of the CC chemokine family. J Immunol. 1996;156:3102-3106.
33. Poltorak AN, Bazzoni F, Smirnova, II, et al. MIP-1 gamma: molecular cloning, expression, and biological activities of a novel CC chemokine that is constitutively secreted in vivo. J Inflamm. 1995;45:207-219.
34. Hara T, Bacon KB, Cho LC. et al. Molecular cloning and functional characterization of a novel member of the C-C chemokine family. J Immunol. 1995;155:5352-5358.
35. Mohamadzadeh M, Knop J, Aliani S, et al. Cytokine expression and antigen-presenting capacity of 4F7+ dendritic cells derived from dermis, spleen, and lymph nodes. Arch Dermatol Res. 1997;289:435-439.
36. Garton KJ, Gough PJ, Raines EW. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol. 2006;79:1105-1116.
37. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin. ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992;187:584-589.
38. Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1328-G1338.
39. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52:171-181.